Navigation Links
Amarantus BioSciences Wins MANF Patent Challenge in Europe
Date:11/20/2012

SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced the Opposition Division of the European Patent Office upheld Amarantus Bioscience's European Patent relating to neurotrophic factor MANF, following opposition by rival Hermo Pharma OY of Finland. 

The Opposition Division held that the Opponent's arguments did not prejudice the maintenance of the Patent as originally granted, with broad claims covering MANF and its derivatives.  The Opponent had not contested the validity of the Patent on the basis of novelty or inventive step, but had objected to the broad scope of the claims. However, after due consideration of comprehensive legal and technical oral submissions from both sides, the Opposition Division rejected the Opponent's arguments and upheld the claims without restriction. 

"This is a highly significant decision for Amarantus, after an extended period of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm Avidity IP, representing Amarantus.  "The Opposition Division's decision validates broad protection for MANF and derivatives across major European jurisdictions."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for bra
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarantus BioSciences Issues CEO Letter to Shareholders
2. Amarantus BioSciences Secures $1.1 Million in Financing
3. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
5. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
6. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
7. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
8. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
9. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Oxis Biotech, Inc. (OXIS), ... OXIS, OXI.PA, announced today that Cassian Yee , ... Cancer Medicine at the University of Texas MD Anderson ... is also Professor, Department of Immunology, Division of Cancer ... Cancer Immunology Research at the University of Texas MD ...
(Date:5/6/2015)... Portland, OR (PRWEB) May 06, 2015 ... executive search and growth strategy for the specialty pharmacy ... Sponser of the 2015 Armada Specialty Pharmacy Summit. The ... Wynn Hotel in Las Vegas and is the largest ... people will be in attendance, from pharmacy providers, pharma/biotech ...
(Date:5/5/2015)... May 5, 2015  23andMe, Inc., the leading personal ... Lupus Research Study in collaboration with Pfizer Inc. ... lupus erythematosus, more commonly known as lupus, into the ... The effort is also in collaboration with the Lupus ... in May. Approximately 1.5 million people in ...
(Date:5/5/2015)... , May 5, 2015  Tikcro Technologies ... was approved to continue trading on OTCQB  Marketplace, ... OTCQB Marketplace allows for a continuous public ... Investors can have real-time quotes and market information ... The OTCQB Marketplace includes U.S. and international ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... 23 Pharmaceutical and biotech partners tasked with cutting costs and improving ... What are the implications of the current economic ... can I harness the knowledge of all employees to improve processes cross-functionally? ... methodologies do I use to show the revenue of quality instead of ...
... WYE ) announced today that it will ... Stock, par value $2.50 per share (the "Convertible Preferred ... As of April 22, 2009, there were 8,896 ... each share of Convertible Preferred Stock is $60.08, which ...
... Provide Proprietary Protein and Small Molecule Products for ... Stem (iPS) CellsLA JOLLA, Calif. and BOSTON, April ... and Stemgent, Inc. ... one-of-a-kind program to provide pharmaceutical and biotechnology companies ...
Cached Biology Technology:Cost-Cutting Plus Value-Add Defines Quality's Role in a Recession 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 3Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 4Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 5Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... in the open-access journal PLoS Biology, streamlines the computation ... genome that influence a particular physical trait, or phenotype. ... Joshua M. Akey, and Leonid Kruglyak, researchers have a ... the genomic elements that produce specific traits. , In ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
... results of a study conducted at Johns Hopkins show that ... attacks, or myocardial infarction, in pigs. In just two months, ... into the animal's damaged heart restored heart function and repaired ... The Hopkins findings, first presented last fall at the 2004 ...
Cached Biology News:Improved statistical tools reveal many linked loci 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3Stem cell therapy successfully treats heart attack in animals 2
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... Adaptor encodes a T7 promoter, lac ... translation initation codon and an N-terminal GST•Tag ... reported to enhance the production and in ... partners. The GST•Tag is a multi-purpose tag ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
Biology Products: